D-0629-2020 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0629-2020 was initiated by Lupin Pharmaceuticals Inc. on Dec 10, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications: High out of specification result observed at stability studies. The recall status is terminated (terminated Apr 29, 2021). Affected quantity: 3,726 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 25, 2019
Initiation Date
Dec 10, 2019
Termination Date
Apr 29, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,726 bottles

Product description

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in a) 90-count bottles (NDC 68180-249-09 and b) 500-count bottles (NDC 68180-249-02); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, INDIA

Reason for recall

Failed Dissolution Specifications: High out of specification result observed at stability studies.

Distribution pattern

Nationwide in the USA

Code information

Lot #: H901787, H901788, Exp March 2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0629-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0629-2020. Report a data issue: hello@regdatalab.com.